| Theme | Prescription of Therapeutics and Monitoring for the Dialysis Patients | |
|---|---|---|
| Title | Therapeutic drug level monitoring | |
| Publish Date | 1999/11 | |
| Author | Teiryou Maeda | Maeda Institute of Renal Research |
| [ Summary ] | Among the drugs monitoring of related factors shows much more right informations than the TDM of administered drugs. For example, in the case of erythroid stimulating drugs (rHuEPO or iron), serum ferritin levels do not always show excessive amounts or deficiencies of iron. Serum iron or iron saturation rates are used to correct indicate the status of iron metabolism. Furthermore, serum transferrin-receptors (sTfR), which are prominent in cases of iron deficiency, show the stimulated erythroid status, under rHuEPO administration. Thus, in cases without rHuEPO administration, sTfR is a good indicator of iron deficiency. In order to properly know the erythroid status it is better to estimate many factors, such as serum iron, iron saturation rates, serum ferritin, MCV, sTfR, etc. In cases where patients are undergoing dialysis therapy, the excretory rout of drugs removes from the kidney to an extra-renal route, such as the bile or other digestive organ systems. It is also important to consider the metabolic pathway of the drugs, in relation to their content in the blood. |
|